Manufacturing

Articles

The commercialization and licensing deal will see Biogen commercialize Xbrane’s Xcimzane, a proposed biosimilar for CIMZIA (certolizumab pegol).

Biogen and Xbrane Ink Agreement for Proposed Biosimilar

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal 

Sandoz will soon begin enrolling patients with neovascular age-related macular degeneration in a Phase III study with its proposed biosimilar to aflibercept.

Sandoz Begins Late-Stage Clinical Development for Biosimilar Aflibercept

AzarGen’s biosimilar, made in iBio’s plant-based system, will be compared to the original molecule in pre-clinical studies.

iBio Supports AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

The partnership will provide cost effective biologics for the world market.

Celltrion and Lonza Sign Contract to Manufacture Remsima Drug Substance

A global agreement with Polpharma Biologics gives Sandoz commercialization rights to a proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis.

Sandoz in Deal to Commercialize Biosimilar Natalizumab

This article provides a review of various 2000-L single-use bioreactors used by biopharmaceutical suppliers for commercial production.

Single-Use Bioreactors Unwrap Commercial Manufacturing Options

Pharmaceutical Technology and BioPharm International will present a Keynote Session on Meeting Bioprocessing Manufacturing Capacity Demands on Wednesday, April 3, 2019, during INTERPHEX 2019 at the Javits Center in New York City.

Biologic Drug Manufacturing Capacity on the Agenda for INTERPHEX 2019 Keynote Series

Editor of Pharmaceutical Technology Europe

To achieve further cost reductions in biosimilar manufacturing, a move away from traditional models is necessary.


Reinventing the Biomanufacturing Wheel

The company is set to expand biologics and fill/finish capacity at its biologics manufacturing sites in Madison, WI, and Bloomington, IN.

Manufacturing, Biosimilars and Biobetters